<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761384</url>
  </required_header>
  <id_info>
    <org_study_id>6th radioimmunotherapy prot.</org_study_id>
    <secondary_id>EudraCT number: 2007-002762-35</secondary_id>
    <nct_id>NCT00761384</nct_id>
  </id_info>
  <brief_title>High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma</brief_title>
  <acronym>HITT</acronym>
  <official_title>A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-cell Lymphoma, Stage II-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the
      liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerable dose (MTD) absorbed dose to the liver, safety and time to treatment failure (TTF)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (OR), complete response (CR), their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy (RIT) in its own right as assessed by positron emission tomography (PET)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>90Y-ibritumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-ibritumomab</intervention_name>
    <description>90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.</description>
    <arm_group_label>90Y-ibritumomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed concent

          -  Age at least 18 years

          -  WHO Performance status 0-3

          -  Histologically verified B-cell lymphoma

          -  Diffuse large B-cell lymphoma and follicular grade III, failing an anthracycline
             containing regimen and patients not found suitable for a second line chemotherapy
             consolidated by high dose chemotherapy (HDCT) with stem cell support or radiotherapy

          -  Transformed B-cell lymphoma, failing first line therapy and not suitable for high dose
             chemotherapy (HDCT) or with a history of HDCT with stem cell support

          -  Follicular lymphoma grade II and I, and other indolent lymphomas must have failed
             second line treatment.

          -  One of these treatments must have contained chemotherapy and rituximab, the latter
             either together with chemotherapy or as maintenance.

          -  The lymphoma must require treatment, Mantle cell lymphoma, failing first line
             treatment,treatment required

          -  Measurable disease and the tumor burden must be acceptable according to the
             investigator

          -  Radiological studies must be performed and a unilateral bone marrow biopsy within 4
             weeks before start of treatment

          -  Bone marrow reserve likely to give a harvest of at least 2x10 6 peripheral CD34+
             stemcells or the existence of such a harvest or a corresponding central harvest

          -  Total bilirubin should not exceed 40 micromole/L

          -  A GFR as measured by Cystatin C of 50 ml/min

          -  HIV, Hepatitis B and C status known

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Known or clinical evidence of CNS involvement

          -  Bone marrow involvement at harvest as measured by biopsy and flow cytometry

          -  Subjects with prior radiation to a field that includes over or equal 25% of their red
             marrow, liver or lung or to both kidneys

          -  Prior chemotherapy or radiotherapy within 4 weeks

          -  Subjects who are pregnant or nursing

          -  Pulmonary involvement, that is not negligible at the discretion of the investigator

          -  Liver involvement of lymphoma

          -  History of hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ola Lind√©n, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell lymphoma</keyword>
  <keyword>Refractory</keyword>
  <keyword>Recurrent</keyword>
  <keyword>90Y-ibritumomab</keyword>
  <keyword>Stem cells support</keyword>
  <keyword>Dosimetry study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

